The company said it plans to sell around 12 million injectable Semaglutide pens in the first year of launch, signalling strong confidence in demand for affordable alternatives to high-priced branded therapies currently dominating the segment.

Semaglutide, the active ingredient in Ozempic and Wegovy, has gained global prominence for its effectiveness in managing type 2 diabetes and its off-label use for weight loss due to appetite-suppressing effects, driving intense interest among patients and healthcare providers alike.

The approval comes ahead of the March 2026 expiry of Novo Nordisk’s patent on Semaglutide, opening the door for Indian generic manufacturers to launch lower-cost versions and compete aggressively in both domestic and international markets.

Dr Reddy’s management said the approval covers the diabetes indication, while regulatory clearance for the obesity drug Wegovy is still awaited, underlining the company’s phased approach to entering the broader weight-loss segment.

The Indian market has already seen rising awareness and uptake of GLP-1 drugs after global pharma giants launched their versions locally last year, with sales reportedly doubling soon after introduction, reflecting strong unmet demand.

Dr Reddy’s plans to collaborate with local partners for the India rollout and has confirmed that it has sufficient manufacturing capacity to meet anticipated demand, an important factor given global supply constraints faced by branded players.

Beyond India, the company also aims to launch Semaglutide in Canada later this year and subsequently expand into other emerging markets, positioning the drug as a key pillar of its international growth strategy.

Executives said Semaglutide is expected to be a major growth driver for the company’s domestic business, which has been bolstered by new launches, selective acquisitions and strategic collaborations over the past year.

The regulatory win comes alongside relatively resilient financial performance, as Dr Reddy’s reported a smaller-than-expected decline in quarterly profit despite challenges in some legacy products.

Revenue from the company’s India business rose sharply, supported by price increases and contributions from recently acquired brands, reflecting strengthening fundamentals in the domestic market.

Overall revenue also exceeded analyst expectations, highlighting how diversification into chronic therapies and branded generics is helping offset pressure in mature segments.

However, the company acknowledged ongoing headwinds from slowing sales of certain oncology generics in the United States, where pricing pressure and competition have intensified.

Industry analysts say Dr Reddy’s early positioning in generic Semaglutide could give it a strong advantage once patents expire, particularly in price-sensitive markets like India where affordability plays a decisive role in adoption.

With diabetes and obesity rates rising steadily across India, the launch of a lower-cost Ozempic alternative could significantly expand patient access while reshaping competitive dynamics in the pharmaceutical sector.

As global demand for weight-loss and diabetes drugs continues to surge, Dr Reddy’s approval underscores India’s growing role as a hub for high-value generics and complex injectables.

The Danish pharmaceutical giant’s price reduction for Wegovy marks a major step toward making innovative weight-loss and diabetes care more affordable and accessible to millions of Indians, fueling positive competition in the fast-growing obesity treatment market.

Danish healthcare leader Novo Nordisk has announced a price reduction of up to 37% for its popular weight-loss drug Wegovy in India.
The move is aimed at making advanced obesity treatment more accessible while strengthening the company’s presence in one of the world’s fastest-growing health markets.

This decision reflects Novo Nordisk’s long-term vision to improve the quality of life for people dealing with obesity and related conditions.
It also demonstrates the company’s responsiveness to both patients and healthcare professionals across India.

With the new price, Wegovy’s highest 2.4 mg dose will now be available for 16,400 rupees per month, a significant drop from its earlier price of over 24,000 rupees. Similarly, the lowest 0.25 mg dose now costs 10,850 rupees, compared to the previous 16,260 rupees.

These reductions come after India’s recent sales tax adjustments, further helping to lower the overall cost for consumers.
Novo Nordisk emphasized that the move was made after careful consultation with doctors, patients, and distributors to ensure broader affordability.

India has quickly become a key battleground in the global obesity treatment sector, which experts predict could reach $150 billion in value by the end of the decade. As lifestyle diseases rise across urban and semi-urban areas, demand for effective and safe weight-loss solutions has surged.

Novo Nordisk’s Wegovy competes closely with Eli Lilly’s Mounjaro, another GLP-1 receptor agonist drug that has seen strong demand since its Indian launch in March. Both medicines help patients achieve sustainable weight loss and improved blood sugar control by mimicking natural hormones that regulate appetite.

In India, the introduction of Wegovy in June 2025 marked a major milestone in Novo Nordisk’s local growth story. The company has since focused on expanding its healthcare partnerships and increasing awareness of obesity as a medical condition requiring structured treatment.

By lowering Wegovy’s price, Novo Nordisk aims to bridge the gap between accessibility and innovation, helping more Indians benefit from world-class therapy. The move also reflects the company’s anticipation of increased competition as generic versions of semaglutide enter the market in 2026.

According to Vikrant Shrotriya, Managing Director of Novo Nordisk India, the price cut represents the company’s commitment to listening to the community. “We have made sure to listen to our patient and doctor communities and take active measures for the benefit of people at large,” he said.

This patient-first approach is expected to strengthen Novo Nordisk’s reputation as a responsible and patient-centric organization.
Healthcare analysts view the strategy as a proactive step to expand reach while building brand loyalty in a highly competitive segment.

Industry experts suggest that the decision is also a strategic preparation for the entry of generics in 2026, allowing Novo Nordisk to maintain a strong foothold. At the same time, the company continues to focus on innovation, safety, and expanding its product portfolio for diabetes and obesity care in India.

The firm’s collaboration with Emcure Pharma for local distribution of Wegovy ensures better reach, especially in Tier-2 and Tier-3 cities.
This partnership model mirrors Eli Lilly’s alliance with Cipla for its Mounjaro product, promoting fair and healthy competition in the Indian market.

The growing rivalry between Novo Nordisk and Eli Lilly is viewed as a positive driver of innovation and accessibility.
Both companies are taking initiatives to make advanced medications available to a broader segment of the Indian population.

Globally, Novo Nordisk has also been working toward price adjustments and healthcare access programs, including agreements with U.S. government programs like Medicare and Medicaid. These efforts highlight the company’s mission to make its therapies affordable and sustainable across markets.

As India continues to grapple with rising obesity and diabetes cases, Novo Nordisk’s pricing decision comes as a welcome relief for patients and doctors alike. It signals a future where life-changing medications become accessible to millions without compromising quality or innovation.

This step by Novo Nordisk is not just a business move — it is a healthcare milestone for India, encouraging wellness, inclusivity, and equitable access to modern medical solutions.